董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David Weinstein | 男 | Director and Chief Executive Officer | 65 | 51.00万美元 | 2.31 | 2025-10-12 |
| Douglas W. Calder | 男 | Director | 58 | 15.75万美元 | 1.28 | 2025-10-12 |
| Mark A. Collins | 男 | Director | 63 | 14.65万美元 | 1.28 | 2025-10-12 |
| James A. McNulty | 男 | Director | 73 | 16.40万美元 | 1.28 | 2025-10-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Nathen Fuentes | 男 | Chief Financial Officer | 43 | 34.50万美元 | 0.27 | 2025-10-12 |
| David Weinstein | 男 | Director and Chief Executive Officer | 65 | 51.00万美元 | 2.31 | 2025-10-12 |
| Nathen Fuentes | 男 | Chief Financial Officer | 42 | 未披露 | 未持股 | 2025-10-12 |
董事简历
中英对照 | 中文 | 英文- David Weinstein
-
David Weinstein，于2024年10月14日，公司董事会委任公司行政总裁兼董事会成员David Weinstein。在加入公司之前，Weinstein先生是Dawson James Securities，Inc.的投资银行业务管理合伙人，自2005年以来一直在该公司工作。在道森詹姆斯任职期间，韦恩斯坦先生为小型生物技术和医疗保健公司直接获得了超过3亿美元的投资。他还牵头推动了个性化癌症诊断领域两家医疗保健公司的合并，并协助其在纳斯达克上市。韦恩斯坦先生获得了圣约翰学院的文科学士学位和马里兰大学的公共管理硕士学位。
David Weinstein On October 14, 2024, the board of directors of the Company appointed David instein, , Chief Executive Officer of the Company and a member of the Board. Immediately prior to joining the Company, Mr. instein was a Managing Partner, Investment Banking at Dawson James Securities, Inc. where he has worked since 2005. While at Dawson James, Mr. instein directly sced over $300 million in investments for small cap biotech and healthcare companies. He also spearheaded the merger of two healthcare companies in personalized cancer diagnostics and assisted in its uplisting on Nasdaq. Mr. instein received his Bachelor of Arts in Liberal Arts from St. John's College and a Masters in Public Management from the University of Maryland. - David Weinstein，于2024年10月14日，公司董事会委任公司行政总裁兼董事会成员David Weinstein。在加入公司之前，Weinstein先生是Dawson James Securities，Inc.的投资银行业务管理合伙人，自2005年以来一直在该公司工作。在道森詹姆斯任职期间，韦恩斯坦先生为小型生物技术和医疗保健公司直接获得了超过3亿美元的投资。他还牵头推动了个性化癌症诊断领域两家医疗保健公司的合并，并协助其在纳斯达克上市。韦恩斯坦先生获得了圣约翰学院的文科学士学位和马里兰大学的公共管理硕士学位。
- David Weinstein On October 14, 2024, the board of directors of the Company appointed David instein, , Chief Executive Officer of the Company and a member of the Board. Immediately prior to joining the Company, Mr. instein was a Managing Partner, Investment Banking at Dawson James Securities, Inc. where he has worked since 2005. While at Dawson James, Mr. instein directly sced over $300 million in investments for small cap biotech and healthcare companies. He also spearheaded the merger of two healthcare companies in personalized cancer diagnostics and assisted in its uplisting on Nasdaq. Mr. instein received his Bachelor of Arts in Liberal Arts from St. John's College and a Masters in Public Management from the University of Maryland.
- Douglas W. Calder
-
Douglas W. Calder，自2015年起，Calder先生担任Vycellix，Inc及其子公司和附属公司的总裁和董事。他还自2023年4月起担任Zevra Therapeutics, Inc.（纳斯达克股票代码：ZVRA）的董事会成员；自2019年6月起担任NextGenNK的董事会成员；自2019年1月起担任BioFlorida的董事会成员，自2018年7月起担任自然免疫协会成员。Calder先生拥有30多年的生命科学高管经验，曾在佛罗里达州的生物技术公司和研究机构担任多个高级管理职务，包括Viragen、Accentia Biopharmaceuticals、BioVest International和佛罗里达州疫苗与基因治疗研究所，还曾在纽约证券交易所成员公司Gruntal & Co.和Dean Witter Reynolds担任注册金融投资组合经理，专注于生命科学股票。考尔德先生获得了佛罗里达州立大学的学士学位。
Douglas W. Calder has served as a director of Zevra Therapeutics, Inc.'s Company since April 2023. Since 2015, Mr. Calder has served as president and financial controller, as well as a director, of Vycellix, Inc. and its subsidiaries and affiliates. He has also served as a member of the board of directors for NextGenNK since 2019; a member of the board of directors of BioFlorida from 2019 to 2025, and, since then, as a special advisor to the board; a member of the Society for Natural Immunity since 2018; and a member of the board of directors of Lunai Bioworks, Inc. (formerly Renovaro, Inc.) since 2024. Mr. Calder has more than 30 years of life science executive experience, having served in various senior executive roles for Florida based biotechnology companies and research institutes, including Viragen, Accentia Biopharmaceuticals, Biovest International and the Vaccine & Gene Therapy Institute of Florida, as well as having formerly served as a registered financial portfolio manager, with a focus on life science equities, with Gruntal & Co. and Dean Witter Reynolds. - Douglas W. Calder，自2015年起，Calder先生担任Vycellix，Inc及其子公司和附属公司的总裁和董事。他还自2023年4月起担任Zevra Therapeutics, Inc.（纳斯达克股票代码：ZVRA）的董事会成员；自2019年6月起担任NextGenNK的董事会成员；自2019年1月起担任BioFlorida的董事会成员，自2018年7月起担任自然免疫协会成员。Calder先生拥有30多年的生命科学高管经验，曾在佛罗里达州的生物技术公司和研究机构担任多个高级管理职务，包括Viragen、Accentia Biopharmaceuticals、BioVest International和佛罗里达州疫苗与基因治疗研究所，还曾在纽约证券交易所成员公司Gruntal & Co.和Dean Witter Reynolds担任注册金融投资组合经理，专注于生命科学股票。考尔德先生获得了佛罗里达州立大学的学士学位。
- Douglas W. Calder has served as a director of Zevra Therapeutics, Inc.'s Company since April 2023. Since 2015, Mr. Calder has served as president and financial controller, as well as a director, of Vycellix, Inc. and its subsidiaries and affiliates. He has also served as a member of the board of directors for NextGenNK since 2019; a member of the board of directors of BioFlorida from 2019 to 2025, and, since then, as a special advisor to the board; a member of the Society for Natural Immunity since 2018; and a member of the board of directors of Lunai Bioworks, Inc. (formerly Renovaro, Inc.) since 2024. Mr. Calder has more than 30 years of life science executive experience, having served in various senior executive roles for Florida based biotechnology companies and research institutes, including Viragen, Accentia Biopharmaceuticals, Biovest International and the Vaccine & Gene Therapy Institute of Florida, as well as having formerly served as a registered financial portfolio manager, with a focus on life science equities, with Gruntal & Co. and Dean Witter Reynolds.
- Mark A. Collins
-
马克·柯林斯（Mark A. Collins）将他40年的职业生涯奉献给了在药物发现中利用计算机，将生物学、人工智能和软件融为一体。他曾在生物技术初创公司、大型制药公司和科技公司中发挥关键作用，带领几家公司成功退出。柯林斯博士目前是UndauntedBio Inc.的首席科学官，他自2022年以来一直在该公司任职，该公司采用独特的人工智能驱动的临床知情、网络医学方法，将现有药物重新用于急性和慢性神经性疼痛情况。在此之前，柯林斯博士是iCometrix的转化服务副总裁，在那里他领导了推动采用AI辅助MRI和数字健康工具的战略，以帮助Pharma提高CNS疗法对一系列神经退行性疾病的转化成功，例如多发性硬化症、阿尔茨海默氏症和帕金森氏症。在加入iCometrix之前，从2017年到2021年，柯林斯博士在Helomics，Corp.任职，最近担任其首席技术官，负责推动AI驱动的肿瘤药物反应和临床结果预测模型的商业实现和上市，进入研究和临床决策支持市场。柯林斯博士还是Purplebio Consulting，LLC的创始人和首席顾问，该公司是一家生命科学咨询公司，提供科学、市场、产品战略咨询以及战术执行。柯林斯博士拥有吉尔福德大学微生物学哲学博士学位和伍尔弗汉普顿大学应用科学理学学士学位。
Mark A. Collins has dedicated his 40 year career to leveraging computers in drug discovery, blending biology, AI, and software. He has played key roles in biotech startups, large Pharma, and tech companies, leading several to successful exits. Dr. Collins is currently the Chief Scientific Officer at UndauntedBio Inc., where he has served since 2022, a company that takes a unique AI driven clinically informed, network medicine approach to repurposing existing drugs for acute and chronic neuropathic pain conditions. Prior to that time, Dr. Collins was the VP Translational Services at Icometrix, where he led the strategy to drive the adoption of AI assisted MRI and digital health tools to help Pharma improve the translational success of CNS therapies for a range of neurodegenerative diseases, such as Multiple Sclerosis, Alzheimer's, and Parkinson's. Prior to Icometrix, from 2017 to 2021, Dr. Collins was at Helomics, Corp., most recently as its Chief Technology Officer, where he drove the technical development and commercial realization of AI driven predictive models of tumor drug response and clinical outcome into the research and clinical decision support markets. Dr. Collins is also the founder and principal consultant of Purplebio Consulting, LLC, a life science consultancy, offering scientific, market, product strategy consulting as ll as tactical execution. Dr. Collins holds a doctorate of Philosophy in Microbiology from the University of Surrey and a Bachelor of Science in Applied Sciences from University of Wolverhampton. - 马克·柯林斯（Mark A. Collins）将他40年的职业生涯奉献给了在药物发现中利用计算机，将生物学、人工智能和软件融为一体。他曾在生物技术初创公司、大型制药公司和科技公司中发挥关键作用，带领几家公司成功退出。柯林斯博士目前是UndauntedBio Inc.的首席科学官，他自2022年以来一直在该公司任职，该公司采用独特的人工智能驱动的临床知情、网络医学方法，将现有药物重新用于急性和慢性神经性疼痛情况。在此之前，柯林斯博士是iCometrix的转化服务副总裁，在那里他领导了推动采用AI辅助MRI和数字健康工具的战略，以帮助Pharma提高CNS疗法对一系列神经退行性疾病的转化成功，例如多发性硬化症、阿尔茨海默氏症和帕金森氏症。在加入iCometrix之前，从2017年到2021年，柯林斯博士在Helomics，Corp.任职，最近担任其首席技术官，负责推动AI驱动的肿瘤药物反应和临床结果预测模型的商业实现和上市，进入研究和临床决策支持市场。柯林斯博士还是Purplebio Consulting，LLC的创始人和首席顾问，该公司是一家生命科学咨询公司，提供科学、市场、产品战略咨询以及战术执行。柯林斯博士拥有吉尔福德大学微生物学哲学博士学位和伍尔弗汉普顿大学应用科学理学学士学位。
- Mark A. Collins has dedicated his 40 year career to leveraging computers in drug discovery, blending biology, AI, and software. He has played key roles in biotech startups, large Pharma, and tech companies, leading several to successful exits. Dr. Collins is currently the Chief Scientific Officer at UndauntedBio Inc., where he has served since 2022, a company that takes a unique AI driven clinically informed, network medicine approach to repurposing existing drugs for acute and chronic neuropathic pain conditions. Prior to that time, Dr. Collins was the VP Translational Services at Icometrix, where he led the strategy to drive the adoption of AI assisted MRI and digital health tools to help Pharma improve the translational success of CNS therapies for a range of neurodegenerative diseases, such as Multiple Sclerosis, Alzheimer's, and Parkinson's. Prior to Icometrix, from 2017 to 2021, Dr. Collins was at Helomics, Corp., most recently as its Chief Technology Officer, where he drove the technical development and commercial realization of AI driven predictive models of tumor drug response and clinical outcome into the research and clinical decision support markets. Dr. Collins is also the founder and principal consultant of Purplebio Consulting, LLC, a life science consultancy, offering scientific, market, product strategy consulting as ll as tactical execution. Dr. Collins holds a doctorate of Philosophy in Microbiology from the University of Surrey and a Bachelor of Science in Applied Sciences from University of Wolverhampton.
- James A. McNulty
-
James A. McNulty曾担任BioDelivery Sciences International， Inc.的董事。自2000年起担任秘书、司库和首席财务官。自2000年以来，他还担任Hopkins Capital Group（一家从事风险投资活动的有限责任公司的附属公司）的首席财务官。Hopkins Capital Group由Dr. Frank E. O'Donnell, Jr.拥有和控制。McNulty先生还兼职担任accententia的财务主管和公司秘书，这是一家拥有专业药品和生物制品商业化资产的控股公司，从2003年到2007年担任Biovest的首席财务官，这是accententia的多数股权子公司。1998年至2000年，他担任Star Scientific， Inc.的首席财务官。2000年至2002年，他担任American Prescription Providers， Inc.的首席财务官/首席运营官。1975年以来，他作为注册会计师从事会计和咨询服务。他共同创立了Pender McNulty & Newkirk，这是佛罗里达州最大的区域注册会计师事务所之一，也是另外两家注册会计师事务所McNulty & Company和McNulty Garcia & Ortiz的创始人/负责人。他是私人公司Quantum Technology Sciences， Inc.的董事。他与Pat Summerall合著了《the Art of Building Relationships on the Links》一书。McNulty先生毕业于南佛罗里达大学，是一名注册会计师，是美国和佛罗里达注册会计师协会的成员，也是Financial Executives International坦帕湾分会的董事会成员。
James A. McNulty serves as CFO for MIRALOGX, LLC, a privately held incubator which develops and licenses pharmaceutical intellectual property to private and public entities. Mr. McNulty is currently Interim CFO for Inhibitor Therapeutics, Inc. (OTCQB: INTI), where he has served since 2022. After leaving public accounting in 1998 after a 26 year career in Tampa as founder of three CPA firms, he served as CFO in the biopharmaceutical indtry, including 3 years with Star Scientific, Inc. (NASDAQ: STSI) and 15 years with BioDelivery Sciences International, Inc. (NASDAQ: BDSI). Mr. McNulty was CEO of MYMD Pharmaceuticals, Inc. (NASDAQ: TNFA) from its inception in 2014 until it became public in early 2020. He served as CFO of MIRA Pharmaceuticals, Inc. from inception in 2020 until it became public in late 2023 as ll as Telomir Pharmaceuticals, Inc (NASDAQ: TELO) from inception in 2021 until shortly before it became public in 2023. He served five years on the board as Lead Director/Audit Committee Chair of CV Sciences, Inc (OTC: CVSI). He has extensive experience in privately held companies, including five years as a Director of Quantum Technology Sciences, Inc. until its acquisition by a public company, and since 2000 as CFO of Hopkins Capital Group, an affiliation of limited liability companies which engage in venture activities primarily in the development of pharmaceuticals, including as CFO of privately owned Defender Pharmaceuticals, Inc. He is a partner in Perfect Golf Event, LLC, an online organizer of over 4,000 charity golf events annually. He co authored with Pat Summerall and published Biness Golf, the art of building relationships on the links. Mr. McNulty's career in accounting and consulting/forensic services includes expert testimony as a Certified Public Accountant, primarily in construction litigation and personal injury cases. He is a 1972 graduate of University of South Florida and a licensed CPA in Florida since 1975. - James A. McNulty曾担任BioDelivery Sciences International， Inc.的董事。自2000年起担任秘书、司库和首席财务官。自2000年以来，他还担任Hopkins Capital Group（一家从事风险投资活动的有限责任公司的附属公司）的首席财务官。Hopkins Capital Group由Dr. Frank E. O'Donnell, Jr.拥有和控制。McNulty先生还兼职担任accententia的财务主管和公司秘书，这是一家拥有专业药品和生物制品商业化资产的控股公司，从2003年到2007年担任Biovest的首席财务官，这是accententia的多数股权子公司。1998年至2000年，他担任Star Scientific， Inc.的首席财务官。2000年至2002年，他担任American Prescription Providers， Inc.的首席财务官/首席运营官。1975年以来，他作为注册会计师从事会计和咨询服务。他共同创立了Pender McNulty & Newkirk，这是佛罗里达州最大的区域注册会计师事务所之一，也是另外两家注册会计师事务所McNulty & Company和McNulty Garcia & Ortiz的创始人/负责人。他是私人公司Quantum Technology Sciences， Inc.的董事。他与Pat Summerall合著了《the Art of Building Relationships on the Links》一书。McNulty先生毕业于南佛罗里达大学，是一名注册会计师，是美国和佛罗里达注册会计师协会的成员，也是Financial Executives International坦帕湾分会的董事会成员。
- James A. McNulty serves as CFO for MIRALOGX, LLC, a privately held incubator which develops and licenses pharmaceutical intellectual property to private and public entities. Mr. McNulty is currently Interim CFO for Inhibitor Therapeutics, Inc. (OTCQB: INTI), where he has served since 2022. After leaving public accounting in 1998 after a 26 year career in Tampa as founder of three CPA firms, he served as CFO in the biopharmaceutical indtry, including 3 years with Star Scientific, Inc. (NASDAQ: STSI) and 15 years with BioDelivery Sciences International, Inc. (NASDAQ: BDSI). Mr. McNulty was CEO of MYMD Pharmaceuticals, Inc. (NASDAQ: TNFA) from its inception in 2014 until it became public in early 2020. He served as CFO of MIRA Pharmaceuticals, Inc. from inception in 2020 until it became public in late 2023 as ll as Telomir Pharmaceuticals, Inc (NASDAQ: TELO) from inception in 2021 until shortly before it became public in 2023. He served five years on the board as Lead Director/Audit Committee Chair of CV Sciences, Inc (OTC: CVSI). He has extensive experience in privately held companies, including five years as a Director of Quantum Technology Sciences, Inc. until its acquisition by a public company, and since 2000 as CFO of Hopkins Capital Group, an affiliation of limited liability companies which engage in venture activities primarily in the development of pharmaceuticals, including as CFO of privately owned Defender Pharmaceuticals, Inc. He is a partner in Perfect Golf Event, LLC, an online organizer of over 4,000 charity golf events annually. He co authored with Pat Summerall and published Biness Golf, the art of building relationships on the links. Mr. McNulty's career in accounting and consulting/forensic services includes expert testimony as a Certified Public Accountant, primarily in construction litigation and personal injury cases. He is a 1972 graduate of University of South Florida and a licensed CPA in Florida since 1975.
高管简历
中英对照 | 中文 | 英文- Nathen Fuentes
Nathen Fuentes，于2023年9月21日加入Telomir Pharmaceuticals，担任Telomir Pharmaceuticals，Inc.的首席财务官、财务主管和秘书。在担任Telomir Pharmaceuticals，Inc. 首席财务官、财务主管和秘书之前，Fuentes先生曾在专业医疗保健行业的中型市场私人股本赞助公司工作，包括2023年5月至2023年9月在Emergence Health Holdings担任首席财务官；2022年7月至2023年5月担任Divergent Dental Group的首席财务官；2019年至2022年7月担任Family First Homecare的首席财务官；2017年至2019年担任Dermatology Medical Partners的首席财务官和合伙人。他还曾于2013年至2017年担任Glytec的财务总监，2012年至2013年担任普华永道的经验丰富的助理，在加入普华永道之前，他曾在住宅建筑公司担任过多个管理职位。Fuentes先生在管理投资者关系、人力资源、财务、会计和收入周期职能的同时，在高杠杆环境中领导收购和有机增长计划的经验丰富。富恩特斯先生在佛罗里达大学获得了市场营销理学学士学位，在费尔菲尔德大学获得了会计学理学硕士学位。Fuentes先生是注册会计师。
Nathen Fuentes most recently served as Chief Financial Officer at Telomir Pharmaceuticals, an emerging leader in age reversal science. Previoly, Mr. Fuentes worked for mid market private equity sponsored companies within the specialty healthcare industry, serving as Chief Financial Officer of Emergence Health Holdings, Divergent Dental Group, Family First Homecare and Dermatology Medical Partners. He also served as the Controller of Glytec, as an Experienced Associate at PricewaterhoeCoopers, and held vario managerial positions with homebuilding companies prior to his experience with PricewaterhoeCoopers. Mr. Fuentes has experience leading acquisition and organic growth initiatives within highly levered environments while managing investor relations, human resces, finance, accounting, and revenue cycle functions. Mr. Fuentes earned his Bachelor of Science in marketing from the University of Florida and his Master of Science in accounting from Fairfield University. Mr. Fuentes is a Certified Public Accountant.- Nathen Fuentes，于2023年9月21日加入Telomir Pharmaceuticals，担任Telomir Pharmaceuticals，Inc.的首席财务官、财务主管和秘书。在担任Telomir Pharmaceuticals，Inc. 首席财务官、财务主管和秘书之前，Fuentes先生曾在专业医疗保健行业的中型市场私人股本赞助公司工作，包括2023年5月至2023年9月在Emergence Health Holdings担任首席财务官；2022年7月至2023年5月担任Divergent Dental Group的首席财务官；2019年至2022年7月担任Family First Homecare的首席财务官；2017年至2019年担任Dermatology Medical Partners的首席财务官和合伙人。他还曾于2013年至2017年担任Glytec的财务总监，2012年至2013年担任普华永道的经验丰富的助理，在加入普华永道之前，他曾在住宅建筑公司担任过多个管理职位。Fuentes先生在管理投资者关系、人力资源、财务、会计和收入周期职能的同时，在高杠杆环境中领导收购和有机增长计划的经验丰富。富恩特斯先生在佛罗里达大学获得了市场营销理学学士学位，在费尔菲尔德大学获得了会计学理学硕士学位。Fuentes先生是注册会计师。
- Nathen Fuentes most recently served as Chief Financial Officer at Telomir Pharmaceuticals, an emerging leader in age reversal science. Previoly, Mr. Fuentes worked for mid market private equity sponsored companies within the specialty healthcare industry, serving as Chief Financial Officer of Emergence Health Holdings, Divergent Dental Group, Family First Homecare and Dermatology Medical Partners. He also served as the Controller of Glytec, as an Experienced Associate at PricewaterhoeCoopers, and held vario managerial positions with homebuilding companies prior to his experience with PricewaterhoeCoopers. Mr. Fuentes has experience leading acquisition and organic growth initiatives within highly levered environments while managing investor relations, human resces, finance, accounting, and revenue cycle functions. Mr. Fuentes earned his Bachelor of Science in marketing from the University of Florida and his Master of Science in accounting from Fairfield University. Mr. Fuentes is a Certified Public Accountant.
- David Weinstein
David Weinstein，于2024年10月14日，公司董事会委任公司行政总裁兼董事会成员David Weinstein。在加入公司之前，Weinstein先生是Dawson James Securities，Inc.的投资银行业务管理合伙人，自2005年以来一直在该公司工作。在道森詹姆斯任职期间，韦恩斯坦先生为小型生物技术和医疗保健公司直接获得了超过3亿美元的投资。他还牵头推动了个性化癌症诊断领域两家医疗保健公司的合并，并协助其在纳斯达克上市。韦恩斯坦先生获得了圣约翰学院的文科学士学位和马里兰大学的公共管理硕士学位。
David Weinstein On October 14, 2024, the board of directors of the Company appointed David instein, , Chief Executive Officer of the Company and a member of the Board. Immediately prior to joining the Company, Mr. instein was a Managing Partner, Investment Banking at Dawson James Securities, Inc. where he has worked since 2005. While at Dawson James, Mr. instein directly sced over $300 million in investments for small cap biotech and healthcare companies. He also spearheaded the merger of two healthcare companies in personalized cancer diagnostics and assisted in its uplisting on Nasdaq. Mr. instein received his Bachelor of Arts in Liberal Arts from St. John's College and a Masters in Public Management from the University of Maryland.- David Weinstein，于2024年10月14日，公司董事会委任公司行政总裁兼董事会成员David Weinstein。在加入公司之前，Weinstein先生是Dawson James Securities，Inc.的投资银行业务管理合伙人，自2005年以来一直在该公司工作。在道森詹姆斯任职期间，韦恩斯坦先生为小型生物技术和医疗保健公司直接获得了超过3亿美元的投资。他还牵头推动了个性化癌症诊断领域两家医疗保健公司的合并，并协助其在纳斯达克上市。韦恩斯坦先生获得了圣约翰学院的文科学士学位和马里兰大学的公共管理硕士学位。
- David Weinstein On October 14, 2024, the board of directors of the Company appointed David instein, , Chief Executive Officer of the Company and a member of the Board. Immediately prior to joining the Company, Mr. instein was a Managing Partner, Investment Banking at Dawson James Securities, Inc. where he has worked since 2005. While at Dawson James, Mr. instein directly sced over $300 million in investments for small cap biotech and healthcare companies. He also spearheaded the merger of two healthcare companies in personalized cancer diagnostics and assisted in its uplisting on Nasdaq. Mr. instein received his Bachelor of Arts in Liberal Arts from St. John's College and a Masters in Public Management from the University of Maryland.
- Nathen Fuentes
Nathen Fuentes最近在Telomir Pharmaceuticals担任首席财务官，该公司是年龄反转科学领域的新兴领导者。Previoly，Fuentes先生曾任职于专业医疗保健产业内的中型市场私募股权赞助公司，担任Emergence Health Holdings、Divergent Dental Group、Family First HomeCare和Dermatology Medical Partners的首席财务官。他还曾担任Glytec的财务总监，在普华永道担任经验丰富的助理，在加入普华永道之前曾在住宅建筑公司担任过多个管理职位。Fuentes先生在管理投资者关系、人力资源、财务、会计和收入周期职能的同时，在高杠杆环境中领导收购和有机增长计划方面拥有丰富的经验。富恩特斯先生获得了佛罗里达大学市场营销理学学士学位和费尔菲尔德大学会计学理学硕士学位。Fuentes先生是一名注册会计师。
Nathen Fuentes most recently served as Chief Financial Officer at Telomir Pharmaceuticals, an emerging leader in age reversal science. Previoly, Mr. Fuentes worked for mid market private equity sponsored companies within the specialty healthcare indtry, serving as Chief Financial Officer of Emergence Health Holdings, Divergent Dental Group, Family First Homecare and Dermatology Medical Partners. He also served as the Controller of Glytec, as an Experienced Associate at PricewaterhoeCoopers, and held vario managerial positions with homebuilding companies prior to his experience with PricewaterhoeCoopers. Mr. Fuentes has experience leading acquisition and organic growth initiatives within highly levered environments while managing investor relations, human resces, finance, accounting, and revenue cycle functions. Mr. Fuentes earned his Bachelor of Science in marketing from the University of Florida and his Master of Science in accounting from Fairfield University. Mr. Fuentes is a Certified Public Accountant.- Nathen Fuentes最近在Telomir Pharmaceuticals担任首席财务官，该公司是年龄反转科学领域的新兴领导者。Previoly，Fuentes先生曾任职于专业医疗保健产业内的中型市场私募股权赞助公司，担任Emergence Health Holdings、Divergent Dental Group、Family First HomeCare和Dermatology Medical Partners的首席财务官。他还曾担任Glytec的财务总监，在普华永道担任经验丰富的助理，在加入普华永道之前曾在住宅建筑公司担任过多个管理职位。Fuentes先生在管理投资者关系、人力资源、财务、会计和收入周期职能的同时，在高杠杆环境中领导收购和有机增长计划方面拥有丰富的经验。富恩特斯先生获得了佛罗里达大学市场营销理学学士学位和费尔菲尔德大学会计学理学硕士学位。Fuentes先生是一名注册会计师。
- Nathen Fuentes most recently served as Chief Financial Officer at Telomir Pharmaceuticals, an emerging leader in age reversal science. Previoly, Mr. Fuentes worked for mid market private equity sponsored companies within the specialty healthcare indtry, serving as Chief Financial Officer of Emergence Health Holdings, Divergent Dental Group, Family First Homecare and Dermatology Medical Partners. He also served as the Controller of Glytec, as an Experienced Associate at PricewaterhoeCoopers, and held vario managerial positions with homebuilding companies prior to his experience with PricewaterhoeCoopers. Mr. Fuentes has experience leading acquisition and organic growth initiatives within highly levered environments while managing investor relations, human resces, finance, accounting, and revenue cycle functions. Mr. Fuentes earned his Bachelor of Science in marketing from the University of Florida and his Master of Science in accounting from Fairfield University. Mr. Fuentes is a Certified Public Accountant.